VERA Projected Dividend Yield
Cl A/Vera Therapeutics Inc ( NASDAQ : VERA )Vera Therapeutics is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Co.'s primary product candidate, atacicept, a self-administered fusion protein that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, with potential for the treatment of IgA nephropathy. Co. has obtained worldwide, exclusive development and commercial rights for MAU868, a monoclonal antibody to treat reactivated BK virus (BKV) infections. MAU868 is a clinical-stage neutralizing monoclonal antibody that is directed against BKV, a polyoma virus. 20 YEAR PERFORMANCE RESULTS |
VERA Dividend History Detail VERA Dividend News VERA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |